Russo-Mancuso G, Di Gregorio F, Passero E, Sciotto A, Mazzarino M C, Malaponte G, Schilirò G
Division of Paediatric Haematology/Oncology, University of Catania, Italy.
Br J Haematol. 1995 Feb;89(2):291-8. doi: 10.1111/j.1365-2141.1995.tb03303.x.
alpha-interferon (alpha-IFN) has been used to treat chronic non-A non-B hepatitis in thalassaemic patients with response rates from 45% to 83%. Unfortunately, treatment with alpha-IFN is associated with side-effects which have a negative effect on the quality of life of the patient. Therefore it would be useful if we could distinguish in advance those patients who would benefit from such therapy from those who would not. In the present study we found that the modification of lymphocyte subsets 20 h after the administration of the first dose of alpha-IFN revealed that relative numbers of T helper lymphocytes (CD4+) increased in three non-responding patients and decreased in five responding patients, whereas those of T suppressor lymphocytes (CD8+), and natural killer cells (CD57+, CD16+) decreased in non-responding patients and increased in responding patients. Therefore analysis of the lymphocyte subsets CD4, CD8, CD57 and CD16 before and 20 h after the administration of alpha-IFN can be used to predict the clinical response to treatment with alpha-IFN.
α干扰素（α-IFN）已被用于治疗地中海贫血患者的慢性非甲非乙型肝炎，有效率为45%至83%。不幸的是，α-IFN治疗会产生副作用，对患者的生活质量有负面影响。因此，如果我们能够提前区分哪些患者会从这种治疗中受益，哪些患者不会，那将很有帮助。在本研究中，我们发现，在给予首剂α-IFN 20小时后淋巴细胞亚群的变化显示，三名无反应患者的辅助性T淋巴细胞（CD4+）相对数量增加，五名有反应患者的该细胞数量减少，而无反应患者的抑制性T淋巴细胞（CD8+）和自然杀伤细胞（CD57+、CD16+）数量减少，有反应患者的这些细胞数量增加。因此，在给予α-IFN之前和之后20小时分析淋巴细胞亚群CD4、CD8、CD57和CD16，可用于预测α-IFN治疗的临床反应。
